Authors:
Bleyer, AJ
Shemanski, LR
Burke, GL
Hansen, KJ
Appel, RG
Citation: Aj. Bleyer et al., Tobacco, hypertension, and vascular disease: Risk factors for renal functional decline in an older population, KIDNEY INT, 57(5), 2000, pp. 2072-2079
Authors:
Chertow, GM
Dillon, M
Burke, SK
Steg, M
Bleyer, AJ
Garrett, BN
Domoto, DT
Wilkes, BM
Wombolt, DG
Slatopolsky, E
Citation: Gm. Chertow et al., A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium - Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients, CLIN NEPHR, 51(1), 1999, pp. 18-26
Authors:
Bleyer, AJ
Burke, SK
Dillon, M
Garrett, B
Kant, KS
Lynch, D
Rahman, SN
Schoenfeld, P
Teitelbaum, I
Zeig, S
Slatopolsky, E
Citation: Aj. Bleyer et al., A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients, AM J KIDNEY, 33(4), 1999, pp. 694-701
Authors:
Perry, JJ
Fleming, RA
Rocco, MV
Petros, WP
Bleyer, AJ
Radford, JE
Powell, BL
Hurd, DD
Citation: Jj. Perry et al., Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease, BONE MAR TR, 23(8), 1999, pp. 839-842